Multi-pronged strategy to support the prevention of diabetes and heart disease

Published Date: 08 Mar 2023

Interventions to improve clinical practice increased the odds that people with type 2 diabetes and heart disease were prescribed the drugs recommended in our study by more than 100%.

Read Full News

Latest News

Do fatalistic attitudes affect clinical outcomes in type 2 diabetes?

University of Wisconsin-Milwaukee and University at Buffalo investigators report that diabetes fatalism is associated with lower mental health-related quality of life over 12 months in African American adults with poorly ...

Big sex differences found in how diet and insulin rewire muscle for better blood sugar

New research found that restricting calories dramatically rewires proteins in rat skeletal muscle, causing molecular changes that boost insulin sensitivity—crucial for blood sugar control in older adults, say scientists ...

Normalizing blood sugars could cut type 2 diabetes risk in half

Prediabetes has long been thought to lead to type 2 diabetes, but according to new Deakin research, for some that isn't always the case.

Why type 1 diabetes is more aggressive in young children

Scientists have made a major breakthrough in understanding why type 1 diabetes is more aggressive in young children, offering the clearest explanation to date of why the condition is particularly difficult to manage when ...

One-hour blood glucose level: A better chance to prevent diabetes

An elevated blood glucose level one hour after the oral glucose tolerance test (OGTT) signals a critical metabolic state—even before prediabetes. Affected individuals respond particularly well to lifestyle interventions. ...

Oral insulin trial marks milestone toward personalized prevention of type 1 diabetes

The Primary Oral Insulin Trial (POInT) investigates whether type 1 diabetes in at-risk children can be prevented through oral insulin treatment. First results mark an important step toward the prevention of type 1 diabetes, ...

Todays Updates

This Week on NeurologyLive® — September 28, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Somnolence Risk, Short-Term Efficacy Drive VMAT2 Inhibitor Choice in Older Adults With Tardive Dyskinesia Isabella Ciccone, MPH

In a discrete choice experiment, somnolence risk and short-term efficacy were the top factors driving vesicular monoamine transporter 2 inhibitor selection for tardive dyskinesia in patients aged 55 years and older.

FDA Approves Tavapadon for the Treatment of Parkinson Disease Isabella Ciccone, MPH

FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.

Gefurulimab Cuts Hospitalizations, Sustains Response in Phase 3 PREVAIL Trial of Myasthenia Gravis Marco Meglio

New PREVAIL trial analyses presented at the 2026 AANEM Annual Meeting showed gefurulimab reduced gMG-related hospitalizations and produced durable symptom and quality-of-life gains through one year.

SHIELD Trial Advances Combination Antiviral for Long COVID Marco Meglio

PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.

Inebilizumab Shows Durable Benefit in MuSK+ Generalized Myasthenia Gravis at AANEM 2026 Marco Meglio

New phase 3 MINT trial analyses presented at the 2026 AANEM Annual Meeting showed inebilizumab produced sustained improvement in MuSK-positive gMG regardless of time since diagnosis.

5 Nephrology Headlines You Missed in August 2026 Alex Hillenbrand

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

Todays Updates

This Week on NeurologyLive® — September 28, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Somnolence Risk, Short-Term Efficacy Drive VMAT2 Inhibitor Choice in Older Adults With Tardive Dyskinesia Isabella Ciccone, MPH

In a discrete choice experiment, somnolence risk and short-term efficacy were the top factors driving vesicular monoamine transporter 2 inhibitor selection for tardive dyskinesia in patients aged 55 years and older.

FDA Approves Tavapadon for the Treatment of Parkinson Disease Isabella Ciccone, MPH

FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.

Gefurulimab Cuts Hospitalizations, Sustains Response in Phase 3 PREVAIL Trial of Myasthenia Gravis Marco Meglio

New PREVAIL trial analyses presented at the 2026 AANEM Annual Meeting showed gefurulimab reduced gMG-related hospitalizations and produced durable symptom and quality-of-life gains through one year.

SHIELD Trial Advances Combination Antiviral for Long COVID Marco Meglio

PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.

Inebilizumab Shows Durable Benefit in MuSK+ Generalized Myasthenia Gravis at AANEM 2026 Marco Meglio

New phase 3 MINT trial analyses presented at the 2026 AANEM Annual Meeting showed inebilizumab produced sustained improvement in MuSK-positive gMG regardless of time since diagnosis.

5 Nephrology Headlines You Missed in August 2026 Alex Hillenbrand

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

Latest News

University of Wisconsin-Milwaukee and University at Buffalo investigators report that diabetes fatalism is associated with lower mental health-related quality of life over 12 months in African American adults with poorly ...

New research found that restricting calories dramatically rewires proteins in rat skeletal muscle, causing molecular changes that boost insulin sensitivity—crucial for blood sugar control in older adults, say scientists ...

Prediabetes has long been thought to lead to type 2 diabetes, but according to new Deakin research, for some that isn't always the case.

Scientists have made a major breakthrough in understanding why type 1 diabetes is more aggressive in young children, offering the clearest explanation to date of why the condition is particularly difficult to manage when ...

An elevated blood glucose level one hour after the oral glucose tolerance test (OGTT) signals a critical metabolic state—even before prediabetes. Affected individuals respond particularly well to lifestyle interventions. ...

The Primary Oral Insulin Trial (POInT) investigates whether type 1 diabetes in at-risk children can be prevented through oral insulin treatment. First results mark an important step toward the prevention of type 1 diabetes, ...

News All Time

Finerenone reduces kidney damage in type 1 diabetes by lowering protein in urine

The drug finerenone has a positive effect on patients with type 1 diabetes and chronic kidney disease. The drug reduces the amount of proteins excreted in the urine of these patients. This reduction indicates that the degree ...

Therapies against cellular aging may help treat metabolic diseases

A growing body of evidence implicates cellular senescence—when cells age and permanently stop dividing—as an important contributor to metabolic dysfunction that can lead to obesity, type 2 diabetes, and metabolic syndrome.

Real-time glucose monitoring with professional support can improve type 1 diabetes control

People with type 1 diabetes achieved significantly better long-term blood glucose when their levels were monitored by health care professionals in real time, via a sensor under the skin, and they received regular advice in ...

Evolutionary comparison points to pigs as superior models for human pancreas and diabetes research

Pancreas development in pigs resembles humans much more closely than does the established mouse model. An international team headed by Helmholtz Munich and the German Center for Diabetes Research (DZD) has now produced a ...

Closed-loop insulin system improves glucose control during pregnancy, clinical trial finds

A collaborative effort across 14 clinical centers in Canada and Australia reports that pregnant women with type 1 diabetes using a closed-loop insulin system spent more time in the pregnancy-specific glucose range than those ...

Healthy lifestyle combined with newer diabetes medications lowers cardiovascular risk, preliminary study suggests

People with type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a greater reduction in risk of major adverse cardiovascular events, including heart attack, stroke or ...

Cartoon-based diabetes education can enhance children's knowledge and physical activity

Researchers at University of Tsukuba reported that using manga as an educational tool in diabetes instruction for children can be equally effective as traditional lectures in enhancing diabetes-related knowledge and engagement ...

New model shows how treating diabetes early makes a difference

Could slightly elevated blood sugar levels lead to serious health problems in the future? A single patient's question sparked nearly a decade of research leading to the development of a landmark model that could shape how ...

Researcher provides new hope in managing diabetic ketoacidosis

A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels in diabetic patients and increasing exercise capacity for better health outcomes. That could be ...

Chemists design candidate drug against diabetes

Researchers from the University at Albany and NYU Grossman School of Medicine have found a way to block a key cellular pathway known to drive chronic inflammation and impaired wound healing in people with diabetes.

Exercise-induced vesicles help protect pancreatic cells and guard against diabetes

Exercise is known for the positive effects on metabolic diseases, partly because of the release of circulating extracellular vesicles (EVs) that mediate intercellular communication and organ crosstalk.

AI-powered diabetes prevention program shows similar benefits to those led by people

Researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health report that an AI-powered lifestyle intervention app for prediabetes reduced the risk of diabetes similarly to traditional, human-led ...

Bariatric surgery in a pill bottle

More than 37 million Americans have type 2 diabetes, a chronic disorder affecting the body's ability to regulate and use sugar. According to the CDC, it's the country's seventh leading cause of death. Type 2 diabetes can ...

Early trigger of diabetic eye disease identified

A team led by UCL scientists has identified a key protein that triggers diabetic retinopathy—a condition caused by high blood sugar damaging the retina's blood vessels and a leading cause of sight loss among working-age ...

African-Caribbean ethnicity key risk factor for sight-threatening diabetic eye disease

People of African-Caribbean ethnicity with Type 2 diabetes are a third more likely to develop a condition called sight-threatening diabetic retinopathy (STDR) than other ethnic groups, according to researchers from King's.

Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program, study suggests

Nearly one-third of people with type 2 diabetes (T2D) in an Indian cohort have achieved remission through an intensive lifestyle intervention program, according to a study published in PLOS One by Pramod Tripathi of the Freedom ...

Recommended News For You

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

Spouses of Cancer Patients May Be at Increased Risk of Suicide

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

Clinical trial sees dramatic results using radiation to treat breast cancer

For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.

Recommended Articles For You

Case Study: Advancing Preclinical Oncology Drug Development with Quantitative Systems Pharmacology 

Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment 

MMA Embolization in Chronic Subdural Hematoma: Evidence, Outcomes, and Gaps 

The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

2.

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

3.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

4.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

5.

The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.

1.

Programmable Cell-Based Therapies for Selective Elimination of Abnormal Hematopoietic Cell Populations

2.

Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options

3.

Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring

4.

The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers

5.

Senescence in Cancer Therapy: Mechanisms, Clinical Relevance, and Therapeutic Implications

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Signs and Symptoms of Leukemia

2.

Signs and Symptoms of Leukemia

3.

Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases

4.

Emerging Concepts in Hematology

5.

Should We Use DARA Up Front As First-Line Therapy in MM?


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot